U.S. Real Estate Stock News

Arthur J. Gallagher (NYSE:AJG) has hired Steve Munday as managing partner of Natural Resources, focusing on renewables and energy transition. Munday previously led the global renewable practice at WTW and brings decades of sector experience to Gallagher. The move signals Gallagher's push to deepen its capabilities in renewables, clean energy and project finance-focused risk solutions. Steve Munday's appointment to lead Natural Resources is a meaningful move that investors should weigh...

Manulife’s principal operating insurer increased its institutional position in SELLAS Life Sciences during the second quarter, while SELLAS reported that its Phase 3 Regal trial had reached 78 of the 80 events needed for final analysis. This combination of a larger stake from a major insurer and an approaching Phase 3 data readout highlights how SELLAS Life Sciences is moving through a capital intensive phase in which clinical outcomes and funding access closely intersect. We will look at...

Penguin Solutions has surged year to date, yet its current checks point to a stock that looks roughly in line with an intrinsic value estimate while earnings multiples still hint at a discount. The share price has climbed 139.7% year to date, which puts extra focus on whether the recent rerating has already absorbed much of the upside. Fresh attention around its role in Lektra's distributed AI data centers can support longer term cash flow expectations, while any slowdown in AI...

Realta Fusion Inc. previously announced a partnership with Madison Gas and Electric and parent MGE Energy to explore a 200-megawatt fusion power plant in Wisconsin, alongside an equity stake and broad technical, siting, and financing support from the utility group. The agreement ties MGE Energy directly into Realta’s fusion research hub at OM Station, linking potential future generation capacity with activity already inside MGE’s service territory. This analysis examines how MGE Energy’s...

Vistra (VST) has filed an omnibus shelf registration for common and preferred stock, giving the utility additional flexibility to raise equity capital as it weighs funding options amid its current share price slide. Recent trading tells a mixed story for Vistra. The share price is down 2.68% on the day at US$147.05 and has declined 11.00% year to date, while the 1-year total shareholder return has fallen 27.56% after a very large 5-year total shareholder return of roughly 8x. In the short...

BioNTech stock has given up much of its early Covid-era surge, with the share price declining about 73.9% over the past five years. Yet the current market still prices the business at levels that screen as expensive on broad valuation checks. For investors, the puzzle is whether a stock that has already retreated this far now offers value, or whether the current tag still asks too much of future performance. Over five years, the share price has fallen about 73.9%, which signals that the...

Darling Ingredients has had a powerful share price run over the past year, yet valuation checks still lean on the cheap side. This puts the recent rally and the current pricing view directly against each other in investors’ minds. The stock has returned 107.9% over the past year. This means anyone looking at Darling Ingredients today is dealing with a very different entry point than twelve months ago. Expectations for the business to keep converting its feedstock and processing operations...

Six Flags Entertainment introduced Flex Pay by Upgrade in September 2026, letting eligible guests buy Season Passes and other products of US$49 or more online and pay over time through fixed monthly installments, with immediate access to pass benefits after activation and no prepayment penalties. This financing option could influence how visitors budget for trips, with more spending potentially shifting toward recurring passes and planned visits rather than one off ticket purchases. This...

GoDaddy (GDDY) has come into focus after recent share price swings, with the stock closing at US$96.37. Investors are weighing its one-month and three-month returns against its longer term performance. Recent swings sit against a mixed backdrop for GoDaddy. The 1-day share price return of 2.96% follows a 7-day share price decline of 7.01%. The 1-year total shareholder return is down 35.14%, while the 3-year total shareholder return is up 28.03%. Compare how GoDaddy stacks up against other...

Thermo Fisher Scientific (NYSE:TMO) is highlighted as a key supplier to organoid intelligence and brain organoid research tools. The company is also cited as a major equipment and consumables provider across multiomics workflows, including spatial omics platforms. Organoid intelligence and multiomics are gaining attention for roles in advanced research, precision medicine, and biological computing applications. This focus on Thermo Fisher's role in organoid intelligence and multiomics only...

MarineMax (HZO) has drawn fresh attention after its share price hovered near US$52.20, with recent returns over the past 3 months and year putting the stock back on many boating retail watchlists. MarineMax’s recent share price return has cooled in the very short term, yet the 90 day share price return of 53.53% and year to date share price return of 116.78% point to strong momentum, broadly echoed by a 1 year total shareholder return of 95.58%. Scan beyond MarineMax and see which retailers...

UDR stock presents a tricky valuation puzzle. The Discounted Cash Flow (DCF) intrinsic value estimate points to a meaningful gap versus the current share price, while market multiples suggest the opposite and recent returns over several years have been weak. Over the past 5 years, UDR has delivered a total return that declined 20.4%, which raises questions about how much of the business quality is already reflected in the current valuation. Future cash flow from its rental portfolio can...

Regeneron Pharmaceuticals (NasdaqGS: REGN) and certain officers face a new securities class action tied to the Phase III Fianlimab-Libtayo study. Filed investors allege the business issued materially false or misleading statements about the trial's statistical assumptions and clinical differentiation. The complaint claims Regeneron did not disclose key issues with the Phase III design that could affect interpretation of the Fianlimab-Libtayo data. This new class action over Fianlimab-Libtayo...

Gentherm (THRM) has drawn fresh attention after recent trading left the stock around $38.33, with short term returns turning negative while longer horizons still show positive total performance for patient shareholders. Recent trading has cooled, with the share price down 5.8% over the past week and about 7.4% over the last month. However, Gentherm still shows a positive 90 day share price return and a 1 year total shareholder return of 10.1%, suggesting earlier momentum has eased rather than...

Intellia Therapeutics (NasdaqGM:NTLA) said the FDA has accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted lonvo-z Priority Review, which signals an accelerated assessment timeline compared with a standard review process. If the BLA is approved, lonvo-z would become the first in vivo CRISPR-based therapy and a one-time treatment option for hereditary angioedema. The FDA’s Priority Review for lonvo-z is important, but investors should weigh it...

Without a fresh headline to point to, Haemonetics (HAE) is still drawing attention after a strong past 3 months and year. Investors are weighing recent share performance against fundamentals and valuation. At a share price of US$101.06, Haemonetics has slipped over the past week but still carries a 30-day share price return of 15.87% and a 90-day move of 29.23%. The 1-year total shareholder return of 88.97% signals strong positive momentum that investors are now weighing against the current...

Viewing insider transactions for Vivani Medical, Inc.'s ( NASDAQ:VANI ) over the last year, we see that insiders were...

Americans are showing increased openness to electric vehicle (EV) ownership, driven by growing confidence in the charging infrastructure, as revealed in the HERE-SBD EV Index 2026. Despite a slight decrease in year-to-date EV market share, consumer optimism is on the rise, with positive perceptions of public charging availability jumping from 28% to 47%. Improvements in EV range, charging speed, and infrastructure expansions have contributed to this shift in sentiment. The study highlights...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Worthington...

We feel now is a pretty good time to analyse Aytu BioPharma, Inc.'s ( NASDAQ:AYTU ) business as it appears the company...

Alphabet stock is coming off a strong three year run, yet current valuation checks suggest the market price may still lag its intrinsic value based on a Discounted Cash Flow (DCF) estimate. With both intrinsic value work and earnings multiple comparisons pointing in the same direction, the key issue for investors is how much of Alphabet’s AI and infrastructure story is already reflected in today’s share price. Alphabet has returned 143.1% over the past three years, which puts recent share...

Bitmine Immersion Technologies stock has produced a strong 3 year return, but the broader valuation checks do not yet paint it as a clear bargain. After a steep 1 year decline and a recent rebound, investors are weighing whether the current share price fairly reflects that mixed record. Over the past 3 years, Bitmine Immersion Technologies has gained 72.9%, which puts recent weakness into context but also raises questions about how much of that strength is already priced in. Future...

Trump Media & Technology Group (DJT) is back in focus after Donald Trump proposed a one-time US$5,000 dividend for every adult U.S. citizen, contingent on Republicans securing full control of Congress. At a share price of US$8.78, Trump Media & Technology Group has seen a sharp decline in year to date share price return of 36.24%, even though the 90 day share price return is up 12.56% and the 1 year total shareholder return is down 48.11%. This points to recent momentum picking up after a...

Recursion Pharmaceuticals stock has had a rough ride over the past few years, and the current market verdict still leans expensive relative to the company’s fundamentals. For anyone looking at the recent slide in Recursion Pharmaceuticals, the key issue is whether the weak historical returns now line up with a more appealing entry point or whether pricing still builds in too much optimism. Over the past 5 years, Recursion Pharmaceuticals has declined about 87%, which signals that long term...